Clinical efficacy of sublingual immunotherapy for grass pollen-induced allergic rhinitis (AR) needs to translate into patient benefit. Patients received Oralair (Stallergenes, Antony, France) in real-life medical practice. Patient-relevant treatment benefits were measured with the AR-specific Patient Benefit Index. Subgroups were analyzed regarding distinct patient characteristics. Data of 883 patients (children, adolescents, and adults) were analyzed. The highest-ranked patient needs referred to having less AR symptoms, being able to go outdoors, and being free in the choice of leisure activities. Most patients (89.2-94.6%) attained at least minimally relevant benefit. All subgroups reported relevant benefits, with significantly higher scores in some subgroups. Treatment with Oralair was associated with considerable patient-relevant benefit in all age groups.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt-2021-0161 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Survey on Treatment-Seeking Patterns in Patients With Allergic Rhinitis.
J Rhinol
November 2024
Department of Otorhinolaryngology-Head and Neck Surgery, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Republic of Korea.
Background And Objectives: The medications preferred by patients for allergic rhinitis and their usage remain unclear. This study investigated treatment-seeking behaviors in patients with allergic rhinitis, including medical treatments, environmental controls, and surgical treatments.
Methods: In this study, a cross-sectional survey was conducted by internal medicine, pediatric, or otorhinolaryngology physicians at university hospitals from January 2022 to April 2022.
Real-world surveillance of standardized quality (SQ) house dust mite sublingual immunotherapy tablets for 3 years in Japan.
Allergy Asthma Proc
January 2025
Department of Pharmacovigilance, Pharmacovigilance and Quality Assurance Group, Torii Pharmaceutical Co., Ltd., Tokyo, Japan.
Standardized quality (SQ) house-dust mite (HDM) sublingual immunotherapy tablets (10,000 Japanese allergy units [JAU], equivalent to 6 SQ-HDM in Europe and the United States) are licensed for the treatment of HDM-induced allergic rhinitis (AR) without age restriction, based on 52-week administration clinical trials. There are no large-scale data on the administration of 10,000 JAU for > 1 year in actual clinical practice. To examine the safety and effectiveness of 10,000 JAU during use for up to 3 years at real-world clinical sites in Japan.
View Article and Find Full Text PDFA study of specific immunoglobulin G4 expression in allergic rhinitis and its value in assessing efficacy and in predicting prognosis of sublingual immunotherapy.
Kaohsiung J Med Sci
December 2024
Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian Province, China.
Allergic rhinitis (AR) is a widespread health issue with a rising global prevalence, and sublingual immunotherapy (SLIT) has shown efficacy in AR treatment. We examined specific immunoglobulin G4 (sIgG4) expression in AR and its role in evaluating SLIT efficacy and predicting patient prognosis. We compared total nasal symptom score (TNSS), total medication score (TMS), visual analogue scale (VAS) score, inflammatory cytokines, and immune function markers in AR patients before and after SLIT.
View Article and Find Full Text PDFAssociation Between Caregiver Burden and Treatment Adherence in Japanese Children With Allergic Rhinitis Receiving Sublingual Immunotherapy.
Cureus
November 2024
Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Tamba, JPN.
Background: Sublingual immunotherapy (SLIT) leads to the long-term remission of allergic rhinitis and requires long-term daily adherence. There are limited studies on the treatment burden or satisfaction of SLIT among caregivers of children treated using SLIT. We aimed to evaluate the association between the treatment burden and satisfaction for pediatric allergic rhinitis caregivers and the clinical factors of their children's SLIT.
View Article and Find Full Text PDF[A preliminary study on the short-term effectiveness and safety of sublingual immunotherapy-spray for patients with respiratory allergy].
Zhonghua Yu Fang Yi Xue Za Zhi
December 2024
Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing210029, China International Centre for Allergy Research, Nanjing Medical University, Nanjing210029, China.
To investigate the short-term effectiveness and safety of sublingual allergen immunotherapy with allergen sprays (SLIT-sprays) in Chinese patients with allergic rhinitis (AR) with or without asthma using real-world data. The retrospective cohort study included 100 patients who received SLIT-sprays in the ENT departments in Hainan Shulan (Boao) Hospital and Boao Super Hospital between October 2023 and August 2024. A questionnaire survey was conducted to collect clinical data on the effectiveness and safety of SLIT-sprays, examining the types and incidence of adverse events (AEs) during treatment, treatments after the occurrence of AEs, and changes in Visual Analog Scale (VAS) scores before and after SLIT-sprays.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!